Company
Boehringer Ingelheim
Boehringer Ingelheim has 73 drugs tracked on RxWires: 3 post-market, 3 approved, 12 in Phase 3, 11 in Phase 2, 44 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Nerandomilast 18 mg - adult formulation | Post-Market | Pulmonary Fibrosis |
| BI-Sifrol® | Post-Market | Parkinson Disease |
| Tiotropium bromide | Post-Market | Pulmonary Disease, Chronic Obstructive |
| SYNJARDY | Approved | |
| PRELUDIN | Approved | |
| PERSANTINE | Approved | |
| Survodutide | Phase 3 | Obesity |
| Zongertinib | Phase 3 | Non-small Cell Lung Cancer |
| verducatib | Phase 3 | Bronchiectasis |
| BI 764198 | Phase 3 | Focal Segmental Glomerulosclerosis |
| Nerandomilast | Phase 3 | Idiopathic Inflammatory Myopathies |
| FDC tiotropium / salmeterol | Phase 3 | Pulmonary Disease, Chronic Obstructive |
| Telmisartan + amlodipine | Phase 3 | Hypertension |
| Aggrenox capsule | Phase 3 | Cerebrovascular Accident |
| Telmisartan | Phase 3 | Hypertension |
| Tiotropium | Phase 3 | Pulmonary Disease, Chronic Obstructive |
| obrixtamig | Phase 3 | Small Cell Lung Cancer (SCLC) |
| Tenecteplase | Phase 3 | Acute Ischemic Stroke |
| Paclitaxel | Phase 2 | Ovarian Neoplasms |
| Ipratropium bromide HFA-134a inhalation aerosol | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| Nintedanib | Phase 2 | Lung Cancer |
| BI 3810477 | Phase 2 | Idiopathic Pulmonary Fibrosis |
| Volasertib | Phase 2 | Leukemia, Myeloid, Acute |
| BI 54903 MD | Phase 2 | Asthma |
| BIBW 2948 BS | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| BIBW 2992 | Phase 2 | Non-small Cell Lung Cancer |
| Terbogrel low dose | Phase 2 | Hypertension, Pulmonary |
| BI 765423 | Phase 2 | Idiopathic Pulmonary Fibrosis |
| BIBW 2992 MA2 40mg/day | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| BI 44847 | Phase 1 | Diabetes Mellitus, Type 2 |
| Persantin® new formulation | Phase 1 | Healthy |
| BI 1819479 | Phase 1 | Healthy |
| afatinib | Phase 1 | Healthy |
| BI 836880 | Phase 1 | Neoplasms |
| BI 1291583 | Phase 1 | |
| BI 4015092 | Phase 1 | Advanced or Metastatic Solid Tumors With KRAS G12D Mutation |
| BI 3034701 (C-14) | Phase 1 | |
| BI 1703880 | Phase 1 | Solid Tumors |
| BI 3821001 | Phase 1 | |
| Vicadrostat | Phase 1 | |
| BI 3810944 | Phase 1 | Solid Tumours |
| Tiotropium/Salmeterol | Phase 1 | Healthy |
| Merck Glucophage® high dose | Phase 1 | Healthy |
| BI 3000202 | Phase 1 | Healthy |
| Epinastine syrup | Phase 1 | Healthy |
| BI 655075 | Phase 1 | Hemorrhage |
| Nevirapine XR low dose | Phase 1 | Healthy |
| BIIB 722 CL solution | Phase 1 | Healthy |
| Microgynon® | Phase 1 | Healthy |
| BIBR 1048 MS low | Phase 1 | Healthy |
| BI 894416 | Phase 1 | Asthma |
| BIBR 796 BS | Phase 1 | Healthy |
| BI 113823 + Ketokonazole | Phase 1 | Healthy |
| Ibuprofen | Phase 1 | Healthy |
| BI 853520 | Phase 1 | Neoplasms |
| BIIX 1 XX - single rising dose | Phase 1 | Healthy |
| Dabigatran etexilate | Phase 1 | Healthy |
| BI 201335 | Phase 1 | Hepatitis C |
| BIBR 1048 MS HPMC capsule | Phase 1 | Healthy |
| BIIX 1 XX - D1 | Phase 1 | Healthy |
| BI 690517 (C-14) | Phase 1 | Healthy |
| Mid-dose bid BI 3731579 | Phase 1 | Healthy |
| BI 3776528 | Phase 1 | Healthy |
| Yasmin® | Phase 1 | Healthy |
| Tamsulosin | Phase 1 | Healthy |
| BI 1015550 | Phase 1 | Healthy |
| BI 425809 | Phase 1 | Healthy |
| BI 3819026 | Phase 1 | Advanced Solid Cancer |
| BI 1831169 | Phase 1 | Solid Tumors |
| Obrixtamig - parenteral 1 | Phase 1 | Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 |
| BI 765179 | Phase 1 | Neoplasms |
| BI 1823911 | Phase 1 | Solid Tumors, KRAS Mutation |
| BI 3968621 | Phase 1 | Advanced Solid Tumour |
Latest
- Exclusivity ends 2026-12-20 (application 206111)
- Obrixtamig moved to Phase 3
Follow Boehringer Ingelheim on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.